EP3323413 - PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB AND TRAMADOL [Right-click to bookmark this link] | Status | Opposition rejected Status updated on 10.03.2023 Database last updated on 02.09.2024 | |
Former | The patent has been granted Status updated on 31.07.2020 | ||
Former | Grant of patent is intended Status updated on 13.04.2020 | ||
Former | Examination is in progress Status updated on 09.12.2019 | ||
Former | Request for examination was made Status updated on 20.04.2018 | ||
Former | The international publication has been made Status updated on 20.01.2017 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Yoo Young Pharm Co., Ltd. 93 Yooyoung Bldg. Hyoryeong-ro Seocho-gu Seoul 06687 / KR | [2018/21] | Inventor(s) | 01 /
KIM, Jung Ju 9-203 120 Seolleung-ro Gangnam-gu Seoul 06093 / KR | 02 /
LEE, Dong Min 906-2101 276 Dongtandaerosibeom-gil Hwaseong-si Gyeonggi-do 18477 / KR | 03 /
KIM, Sun Kyoung 609-2409 393 Hyoseo-ro Gyeyang-gu Incheon 21125 / KR | [2018/21] | Representative(s) | Louis Pöhlau Lohrentz Patentanwälte Postfach 30 55 90014 Nürnberg / DE | [2018/21] | Application number, filing date | 16824623.9 | 29.06.2016 | [2018/21] | WO2016KR06930 | Priority number, date | KR20150099808 | 14.07.2015 Original published format: KR 20150099808 | [2018/21] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017010706 | Date: | 19.01.2017 | Language: | KO | [2017/03] | Type: | A1 Application with search report | No.: | EP3323413 | Date: | 23.05.2018 | Language: | EN | [2018/21] | Type: | B1 Patent specification | No.: | EP3323413 | Date: | 02.09.2020 | Language: | EN | [2020/36] | Search report(s) | International search report - published on: | KR | 19.01.2017 | (Supplementary) European search report - dispatched on: | EP | 31.01.2019 | Classification | IPC: | A61K31/415, A61K31/135, A61K47/38, A61K47/44, A61K47/36, A61K9/24 | [2019/09] | CPC: |
A61K9/209 (EP,US);
A61K31/135 (EP,RU,US);
A61K31/635 (CN);
A61K9/4866 (US);
A61K31/133 (EP,US);
A61K31/137 (CN);
A61K31/18 (EP,US);
A61K31/415 (EP,RU,US);
A61K47/14 (CN,RU);
A61K47/20 (CN);
A61K47/26 (CN,RU);
A61K47/32 (CN,US);
A61K47/36 (EP,US);
A61K47/38 (EP,CN,RU,US);
A61K47/44 (EP,CN,RU,US);
A61K9/4808 (US);
A61P25/04 (EP);
A61P29/00 (EP,CN,RU);
A61P43/00 (EP)
(-)
| C-Set: |
A61K31/137, A61K2300/00 (CN);
A61K31/635, A61K2300/00 (CN) |
Former IPC [2018/21] | A61K31/415, A61K31/135, A61K47/38, A61K47/44, A61K47/36 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/21] | Extension states | BA | 18.01.2018 | ME | 18.01.2018 | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT CELECOXIB UND TRAMADOL | [2018/21] | English: | PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB AND TRAMADOL | [2018/21] | French: | COMPOSITION PHARMACEUTIQUE CONTENANT DU CÉLÉCOXIB ET DU TRAMADOL | [2018/21] | Entry into regional phase | 18.01.2018 | Translation filed | 18.01.2018 | National basic fee paid | 18.01.2018 | Search fee paid | 18.01.2018 | Designation fee(s) paid | 18.01.2018 | Examination fee paid | Examination procedure | 18.01.2018 | Examination requested [2018/21] | 18.01.2018 | Date on which the examining division has become responsible | 30.08.2019 | Amendment by applicant (claims and/or description) | 12.12.2019 | Despatch of a communication from the examining division (Time limit: M02) | 24.02.2020 | Reply to a communication from the examining division | 14.04.2020 | Communication of intention to grant the patent | 28.07.2020 | Fee for grant paid | 28.07.2020 | Fee for publishing/printing paid | 28.07.2020 | Receipt of the translation of the claim(s) | Opposition(s) | Opponent(s) | 01
02.06.2021
04.06.2021
ADMISSIBLE Dehmel & Bettenhausen Patentanwälte PartmbB Herzogspitalstr. 11 80331 München / DE Opponent's representative Peters, Hajo Dehmel & Bettenhausen Patentanwälte PartmbB Herzogspitalstraße 11 80331 München / DE | [2021/28] |
Former [2021/27] | |||
Opponent(s) | 01
02.06.2021
Dehmel & Bettenhausen Patentanwälte PartmbB Herzogspitalstr. 11 80331 München / DE Opponent's representative Dehmel, Albrecht Dehmel & Bettenhausen Patentanwälte PartmbB Herzogspitalstraße 11 80331 München / DE | 17.06.2021 | Invitation to proprietor to file observations on the notice of opposition | 22.10.2021 | Reply of patent proprietor to notice(s) of opposition | 24.10.2022 | Cancellation of oral proceeding that was planned for 01.12.2022 | 24.11.2022 | Date of despatch of rejection of opposition | 01.12.2022 | Date of oral proceedings | 04.12.2022 | Legal effect of rejection of opposition [2023/15] | Fees paid | Renewal fee | 28.06.2018 | Renewal fee patent year 03 | 26.06.2019 | Renewal fee patent year 04 | 31.03.2020 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 29.06.2016 | AL | 02.09.2020 | CY | 02.09.2020 | CZ | 02.09.2020 | DK | 02.09.2020 | EE | 02.09.2020 | FI | 02.09.2020 | HR | 02.09.2020 | LT | 02.09.2020 | LV | 02.09.2020 | MC | 02.09.2020 | MK | 02.09.2020 | RO | 02.09.2020 | RS | 02.09.2020 | SE | 02.09.2020 | SI | 02.09.2020 | SK | 02.09.2020 | SM | 02.09.2020 | BG | 02.12.2020 | NO | 02.12.2020 | GR | 03.12.2020 | IS | 02.01.2021 | PT | 04.01.2021 | IE | 29.06.2021 | LU | 29.06.2021 | [2024/22] |
Former [2023/33] | HU | 29.06.2016 | |
AL | 02.09.2020 | ||
CY | 02.09.2020 | ||
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
MC | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
IE | 29.06.2021 | ||
LU | 29.06.2021 | ||
Former [2023/30] | AL | 02.09.2020 | |
CY | 02.09.2020 | ||
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
MC | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
IE | 29.06.2021 | ||
LU | 29.06.2021 | ||
Former [2022/21] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
MC | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
IE | 29.06.2021 | ||
LU | 29.06.2021 | ||
Former [2022/18] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
MC | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
LU | 29.06.2021 | ||
Former [2022/08] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
MC | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
Former [2021/37] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
DK | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
Former [2021/36] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SI | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
Former [2021/28] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SK | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
Former [2021/25] | AL | 02.09.2020 | |
CZ | 02.09.2020 | ||
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
IS | 02.01.2021 | ||
PT | 04.01.2021 | ||
Former [2021/22] | CZ | 02.09.2020 | |
EE | 02.09.2020 | ||
FI | 02.09.2020 | ||
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RO | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
SM | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
PT | 04.01.2021 | ||
Former [2021/21] | FI | 02.09.2020 | |
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
PT | 04.01.2021 | ||
Former [2021/10] | FI | 02.09.2020 | |
HR | 02.09.2020 | ||
LT | 02.09.2020 | ||
LV | 02.09.2020 | ||
RS | 02.09.2020 | ||
SE | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
Former [2021/09] | FI | 02.09.2020 | |
LT | 02.09.2020 | ||
SE | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
GR | 03.12.2020 | ||
Former [2021/08] | FI | 02.09.2020 | |
LT | 02.09.2020 | ||
SE | 02.09.2020 | ||
BG | 02.12.2020 | ||
NO | 02.12.2020 | ||
Former [2021/07] | FI | 02.09.2020 | |
LT | 02.09.2020 | ||
NO | 02.12.2020 | Documents cited: | Search | [A]WO2009049405 (LABOPHARM INC [CA], et al) [A] 1-10 * paragraph [0045]; claims 1-12 *; | [Y]US2009175939 (BOSSE PAUL [US], et al) [Y] 1-10 * paragraph [0164] - paragraph [0165]; claims 1-3, 8, 10 *; | [Y]WO2015016695 (RAAM DE SAHUAYO S A DE C V LAB [MX]) [Y] 1-10* claim - * | International search | [A]KR20040067969 (AMOREPACIFIC CORP) [A] 1-10 * See the entire document. *; | [Y]KR20080104910 (HANA PHARM CO LTD [KR]) [Y] 1-10 * See claims 1-9. *; | [A]KR20110122287 (SAMYANG HOLDINGS CORP [KR]) [A] 1-10* See abstract. *; | [Y]KR20130069484 (SAMYANG BIOPHARMACEUTICALS [KR]) [Y] 2-7 * See claims 1-13. *; | [Y]JP2014221797 (ESTEVE LABOR DR) [Y] 1-10 * See claims 1-13. * | Opposition | KR20080104910 | WO2009049405 | US2009175939 | WO2011045075 | KR20130069484 | WO2015016695 | KR20150099808 | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CELEBREX safely and effectively. See full prescribing information for CELEBREX", CELEBREX, (20180601), pages 1 - 22, XP055951645 | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ULTRA ER ", ULTRAMER, (19950101), pages 1 - 37, XP055951647 |